In vitro analysis reveals that CMC/AMX/nHA improves dentin hypersensitivity treatment in periodontitis, suggesting effective drug delivery and antimicrobial properties.
This study explores the potential of Carboxymethy Cellulose/Amoxicillin/Nano-Hydroxyapatite suspensions (CMC/AMX/nHA) for the treatment of dentin hypersensitivity, particularly in the context of periodontitis treatment. The CMC/AMX/nHA suspension was compared with the commonly used clinical desensitizing agent Bifluorid12 and the broad-spectrum antibiotic Minocycline Hydrochloride. Microscopic observation and antimicrobial experiments were conducted to quantitatively and qualitatively assess the ability of CMC/AMX/nHA to seal dentinal tubules and its antimicrobial properties. Additionally, a resin bonding experiment was performed to evaluate the effect of CMC/AMX/nHA on dentin bonding. The research results indicate that CMC/AMX/nHA demonstrates good biocompatibility, with excellent drug delivery capabilities, bacterial growth inhibition, and no interference with subsequent repair treatments during desensitization therapy. These findings suggest that CMC/AMX/nHA has high translational potential and may be effectively applied in clinical oral medicine.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: